# A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)

> **NCT04583280** · PHASE3 · TERMINATED · sponsor: **Janssen Research & Development, LLC** · enrollment: 28 (actual)

## Conditions studied

- Respiratory Tract Infections

## Interventions

- **DRUG:** Rilematovir
- **DRUG:** Rilematovir X mg/kg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04583280
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-09-06
- **Primary completion:** 2022-03-18
- **Final completion:** 2022-03-18
- **Target enrollment:** 28 (ACTUAL)
- **Why stopped:** Janssen made the strategic decision to discontinue the DAISY study. This decision is not based on any safety concerns.
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04583280

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04583280, "A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04583280. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*